We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Blood Test to Help Physicians Prevent Major Cardiovascular Events in Women with Lupus

By LabMedica International staff writers
Posted on 08 Nov 2022
Print article
Image: New test helps predict heart disease in lupus patients (Photo courtesy of AMPEL)
Image: New test helps predict heart disease in lupus patients (Photo courtesy of AMPEL)

Female lupus patients aged 35-44 years are 50-times more likely to have a fatal cardiovascular event than other women in their age group. One-third of all lupus deaths are due to unrecognized coronary artery disease leading to heart attacks and strokes. Now, a genetic precision medicine test for lupus patients could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies. The breakthrough approach characterizes inherited genetic markers in blood samples that drive pathways that can be targeted by drugs.

AMPEL BioSolutions’ (Charlottesville, VA, USA) CardioGENE lab test, only a concept for the last few years, is now ready for development for practical use as a decision support biomarker test. AMPEL's innovative approach linking genetic predisposition to molecular pathways targeted by drugs may greatly impact health care by allowing physicians to identify cardiovascular disease risk following lupus diagnosis and select appropriate prophylactic treatments.

By identifying the DNA-driven pathways, CardioGENE will allow health care professionals to prevent serious cardiovascular events with prophylactic targeted treatment. This is the first time cardiovascular genetic risk factors that result in strokes and heart attacks have been identified in immune and inflammatory system genes even when a patient does not smoke, have elevated cholesterol or high blood pressure. Importantly, FDA-approved drugs that target inflammatory cytokines such as IL6 as well as immune cells are candidates for prophylactic therapy.

"CardioGENE marks a diversification of AMPEL's portfolio into genetic testing, and we are extremely excited to share our results," said Dr. Amrie Grammer, AMPEL Co-Founder, President and Chief Scientific Officer. "We are confident that CardioGENE will make a difference in the lives of lupus patients, especially young women who disproportionately suffer from the disease's cardiovascular impacts."

"This research not only contributes to our understanding of the genetic basis of the increased frequency of cardiovascular events in patients living with lupus, but also provides practical information on new molecular pathways contributing to atherosclerotic cardiovascular disease," said Dr. Peter Lipsky, AMPEL Co-Founder, CEO and Chief Medical Officer. "We believe this work will usher in new approaches to ameliorate one of the leading causes of death in lupus patients."

Related Links:
AMPEL BioSolutions 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.